|
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia. |
| |
|
Consulting or Advisory Role - Abbvie; CTI BioPharma Corp |
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Stemline Therapeutics |
| |
|
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Jazz Pharmaceuticals; Novartis; Pfizer |
Speakers' Bureau - Abbvie; Amgen; Jazz Pharmaceuticals; Novartis |
| |
|
Consulting or Advisory Role - Abbvie/Genentech; Agios; Astellas Pharma; Bristol-Myers Squibb/Celgene; Forty Seven; Macrogenics; SERVIER; Stemline Therapeutics |
Research Funding - Astex Pharmaceuticals (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Immune-Onc Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Syndax (Inst) |
| |
|
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma (Inst); Bio-Path Holdings, Inc (Inst); Celgene (Inst); Celyad (Inst); CicloMed (Inst); Cleave Biosciences (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); incyte (Inst); Novartis (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); Seagen (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst) |
| |
Stephen Anthony Strickland |
Consulting or Advisory Role - Abbvie; BerGenBio; Genentech; Kura Oncology; Syros Pharmaceuticals |
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); ECOG-ACRIN (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst); Menarini (Inst); PrECOG (Inst) |
| |
|
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Foghorn Therapeutics; Forty Seven; Genentech; Ipsen; Kite, a Gilead company; Kura Oncology; MorphoSys; MorphoSys; Novartis; Pfizer; Seagen; Takeda; Trillium Therapeutics; Trovagene |
Research Funding - Abbvie (Inst); agios (Inst); Bristol-Myers Squibb (Inst); SERVIER (Inst); Takeda (Inst) |
| |
|
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Celgene; Daiichi Sankyo; Glycomimetics; Immunogen; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Kura Oncology; Macrogenics; Novartis; Pfizer; Takeda; Trillium Therapeutics |
Speakers' Bureau - Abbvie/Genentech; Agios; Celgene; Incyte; Jazz Pharmaceuticals; Novartis |
Research Funding - Abbvie; Abbvie (Inst); Agios (Inst); ALX Oncology (Inst); Amgen (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); Glycomimetics (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Macrogenics (Inst); Novartis (Inst); PTC Therapeutics (Inst) |
Other Relationship - Celgene; Glycomimetics |
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo |
| |
|
Employment - Jazz Pharmaceuticals |
Stock and Other Ownership Interests - Jazz Pharmaceuticals |
| |
|
Employment - Jazz Pharmaceuticals |
Stock and Other Ownership Interests - Jazz Pharmaceuticals |
| |
|
No Relationships to Disclose |
| |
Vijayalakshmi Chandrasekaran |
Employment - Jazz Pharmaceuticals |
Stock and Other Ownership Interests - Jazz Pharmaceuticals |
| |
|
Employment - Jazz Pharmaceuticals |
Stock and Other Ownership Interests - Jazz Pharmaceuticals |
| |
|
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Fujifilm; GlaxoSmithKline; Jazz Pharmaceuticals; Menarini |
Research Funding - Astellas Pharma (Inst); Fujifilm (Inst) |
Expert Testimony - Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma |